Biomotion Sciences (SLXN) Company Overview

Profile

Full Name:

Silexion Therapeutics Corp

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

April 7, 2021

Indexes:

Not included

Description:

Biomotion Sciences focuses on developing innovative solutions in the field of biotechnology, aiming to improve health outcomes through advanced scientific research and technology.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 29, 2024

Analyst ratings

Recent major analysts updates

Nov 1, 24 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
SLXN
globenewswire.comJanuary 29, 2025

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company's ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282932). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.3 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about January 30, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
SLXN
benzinga.comJanuary 16, 2025

Silexion Therapeutics Corp.  SLXN revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
SLXN
globenewswire.comJanuary 15, 2025

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company's ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accompanying warrant. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about January 17, 2025, subject to the satisfaction of customary closing conditions.

Silexion Therapeutics Announces 1-for-9 Reverse Share Split
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
SLXN
globenewswire.comNovember 22, 2024

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives

FAQ

  • What is the ticker symbol for Biomotion Sciences?
  • Does Biomotion Sciences pay dividends?
  • What sector is Biomotion Sciences in?
  • What industry is Biomotion Sciences in?
  • What country is Biomotion Sciences based in?
  • When did Biomotion Sciences go public?
  • Is Biomotion Sciences in the S&P 500?
  • Is Biomotion Sciences in the NASDAQ 100?
  • Is Biomotion Sciences in the Dow Jones?
  • When does Biomotion Sciences report earnings?
  • Should I buy Biomotion Sciences stock now?

What is the ticker symbol for Biomotion Sciences?

The ticker symbol for Biomotion Sciences is NASDAQ:SLXN

Does Biomotion Sciences pay dividends?

No, Biomotion Sciences does not pay dividends

What sector is Biomotion Sciences in?

Biomotion Sciences is in the Healthcare sector

What industry is Biomotion Sciences in?

Biomotion Sciences is in the Biotechnology industry

What country is Biomotion Sciences based in?

Biomotion Sciences is headquartered in Israel

When did Biomotion Sciences go public?

Biomotion Sciences's initial public offering (IPO) was on April 7, 2021

Is Biomotion Sciences in the S&P 500?

No, Biomotion Sciences is not included in the S&P 500 index

Is Biomotion Sciences in the NASDAQ 100?

No, Biomotion Sciences is not included in the NASDAQ 100 index

Is Biomotion Sciences in the Dow Jones?

No, Biomotion Sciences is not included in the Dow Jones index

When does Biomotion Sciences report earnings?

The date for Biomotion Sciences's next earnings report has not been announced yet

Should I buy Biomotion Sciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions